Table 2.
Grade 2 or greater toxicities observed in ≥1 patient
| Nivolumab–ipilimumab (n = 10) n (%) |
Nivolumab–ipilimumab plus CBM588 (n = 19) n (%) |
|||||
|---|---|---|---|---|---|---|
| Grade 2 | Grade 3 | Grade 4 | Grade 2 | Grade 3 | Grade 4 | |
| Overall | 2 (20) | 5 (50) | 0 (0) | 6 (32) | 9 (47) | 1 (5) |
| Neutrophil count decreased | 1 (10) | 1 (5) | ||||
| Fatigue | 1 (10) | 3 (19) | 1 (5) | |||
| Glucose intolerance | 1 (10) | 1 (5) | 1 (5) | |||
| Diarrhea | 1 (10) | 1 (5) | 1 (5) | |||
| Adrenal insufficiency | 3 (19) | 1 (5) | ||||
| Rash maculopapular | 2 (11) | 1 (5) | ||||
| Acute kidney injury | 1 (10) | 1 (5) | 1 (5) | |||
| Abdominal pain | 1 (5) | |||||
| Alkaline phosphatase increase | 1 (5) | |||||
| Acidosis | 1 (5) | |||||
| Chest wall pain | 1 (5) | |||||
| Pancreatitis | 1 (5) | |||||
| Transaminitis | 1 (10) | 5 (26) | 1 (5) | |||
| Pruritus | 1 (10) | |||||
| Dehydration | 1 (10) | |||||
| Hypothyroidism | 1 (10) | 3 (19) | ||||
| Hyperthyroidism | 3 (19) | |||||
| Arthralgia or myalgia | 4 (22) | |||||
| Weight gain | 2 (11) | |||||